Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pigment epithelium-derived factor: characterization, genomic organization and sequence of the PEDF gene

a pigment epithelium and gene technology, applied in the field of neuronotrophic, neuronotrophic and gliastatic proteins, can solve the problem of difficult at best for further study of ped

Inactive Publication Date: 2006-01-12
US DEPT OF HEALTH & HUMAN SERVICES
View PDF15 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] It is yet another object of the present invention to provide PEDF and equivalent proteins produced in accordance with such a recombinant method, wherein the PEDF and equivalent proteins so produced are free from the risks associated with the isolation of PEDF from naturally-occurring source organisms.

Problems solved by technology

Unfortunately, the low abundance of PEDF in fetal human eye and furthermore, the rare availability of its source tissue, especially in light of restrictions on the use of fetal tissue in research and therapeutic applications, make further study of PEDF difficult at best.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pigment epithelium-derived factor: characterization, genomic organization and sequence of the PEDF gene
  • Pigment epithelium-derived factor: characterization, genomic organization and sequence of the PEDF gene
  • Pigment epithelium-derived factor: characterization, genomic organization and sequence of the PEDF gene

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0076] This example describes the trypsin digestion of PEDF and the amino acid sequencing of the resulting fragments.

[0077] PEDF was purified from the medium of a primary culture of human fetal RPE cells by high performance liquid chromatography (HPLC). The HPLC-purified PEDF was then reduced and alkylated. Afterwards, it was dried and redissolved in 50 μl of CRA buffer (8 M urea, 0.4 M ammonium carbonate, pH 8.0), and 5 μl of 45 mM dithiothreitol (DTT) (Calbiochem, San Diego, Calif.) were added. After heating at 50° C. for 15 minutes, the solution was cooled, and 5 μl of 100 mM iodoacetic acid (Sigma Chem. Co., St. Louis, Mo.) were added. After 15 minutes, the solution was diluted to a concentration of 2 M urea and subjected to trypsin digestion (Boehringer-Mannheim, Indianapolis, Ind.) for 22 hours at 37° C. using an enzyme:substrate ratio of 1:25 (wt / wt). Tryptic peptides were separated by narrowbore, reverse-phase HPLC on a Hewlett-Packard 1090 HPLC, equipped with a 1040 diode ...

example 2

[0079] This example describes the construction of oligonucleotides, based on the peptide sequences of Example 1, the use of the oligonucleotides in the isolation of PEDF cDNA, and the sequencing of PEDF cDNA.

[0080] Based on the JT-3 and JT-8 peptide sequences of Example 1 and codon usage data, the oligonucleotides oFS5665 (SEQ ID NO:4): 5′-AGYAAYTTYTAYGAYCTSTA-3′ and oFS5667 (SEQ ID NO:5): 5′-CTYTCYTCRTCSAGRTARAA-3′ were constructed on an ABI 392 DNA / RNA Synthesizer and used as primers in a polymerase chain reaction (PCR).

[0081] A human fetal eye Charon BS cDNA library (obtained from Dr. A. Swaroop of the Kellog Eye Institute) was amplified once (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989)) and screened by PCR (Friedman et al., Screening of λgt11 Libraries, In: PCR Protocols: A Guide to Methods and Applications, Innis et al., eds., Academic Press, NY (1990), pp. 253-260) using a Techne thermal cycler a...

example 3

[0085] This example describes the construction of an expression vector for the production of recombinant PEDF.

[0086] An expression vector was constructed using the plasmid πFS17, which contains the full-length cDNA for human PEDF as described in Example 2. The PEDF coding sequence was placed under the control of a bacteriophage lambda PL promoter present in the plasmid pEV-vrf2 (Crowl et al., Gene, 38, 31-38 (1985)) to obtain the vector pEV-BH. This was accomplished by obtaining a BamH I-Hind III fragment of πFS17 comprising a portion of the PEDF coding region (namely, nucleotide 245 to 1490 of SEQ ID NO:1), digesting plasmid pEV-vrf2 with EcoR I-Hind III, rendering both fragments blunt by means of a fill-in reaction at the BamH I and EcoR I ends with DNA polymerase I (Klenow fragment), and ligating the resultant blunt-ended / compatible-ended fragments to each other. The resultant vector pEV-BH places a distance of 8 nucleotide between the Shine-Dalgarno (SD) sequence and the PEDF c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Densityaaaaaaaaaa
Login to View More

Abstract

Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.

Description

[0001] This application is a continuation-in-part of application Ser. No. 08 / 257,963 filed on Jun. 7, 1994, which is a continuation-in-part of application Ser. No. 07 / 952,796 filed on Sep. 24, 1992.TECHNICAL FIELD OF THE INVENTION [0002] This invention relates to a neurotrophic, neuronotrophic and gliastatic protein. More specifically, this invention relates to the biological properties of a protein known as pigment epithelium-derived factor (PEDF) and recombinant forms of the protein. This invention also relates to a truncated version of PEDF that is referred to as rPEDF. In addition to PEDF and rPEDF and functionally equivalent proteins, this invention relates to nucleic acids that encode rPEDF, and fragments thereof, to vectors comprising such nucleic acids, to host cells into which such vectors have been introduced, and to the use of these host cells to produce such proteins. BACKGROUND OF THE INVENTION [0003] Pigment epithelium-derived factor, otherwise known as pigment epithel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/06C07H21/04C07K14/705A61K35/30A61K38/00G01N33/53A61K38/22A61P25/00A61P27/02C07K14/81C07K16/24C07K16/38C12N15/02C12P21/02C12P21/08C12R1/19
CPCA61K38/00C07K16/38C07K14/811C07K14/475A61P25/00A61P27/02A61P29/00A61P43/00A61P9/00
Inventor CHADER, GERALDRODRIGUEZ, IGNACIOTOMBRAN-TINK, JOYCEBECERRA, SOFIASTEELE, FINTANJOHNSON, LINCOLN
Owner US DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products